SALMON: Solvent accessibility, ligand binding, and mapping of ligand orientation by NMR spectroscopy

Journal of Medicinal Chemistry

Volumn 51, Issue 1, 2008, Pages 1-3

  Ludwig, Christian ^a   Michiels, Paul J A ^c   Wu, Xiaoqiu ^b   Kavanagh, Kathryn L ^b   Pilka, Ewa ^b   Jansson, Anna ^b   Oppermann, Udo ^b   Günther, Ulrich L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; CARICOTAMIDE; LIGAND; PRODRUG; QUINONE OXIDOREDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SOLVENT; SUCCINATE DEHYDROGENASE (UBIQUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; LIGAND BINDING; MAGNETISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; PROCESS OPTIMIZATION; SALMON METHOD; SOLVENT EFFECT; WATERLOGSY METHOD;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BINDING SITES; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); PRODRUGS; PROTEIN BINDING; SOLVENTS; WATER;

EID: 37849034596     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701020f     Document Type: Article

References (14)

1. Balaram, P.; Bothner-By, A.; Breslow, E. Localization of tyrosine at the binding site of neurophysin II by negative nuclear Overhauser effects. J. Am. Chem. Soc. 1972, 94, 4017-4018.
2. Balaram, P.; Bothner-By, A.; Dadok, J. Negative nuclear Overhauser effects as probes of macromolecular structure. J. Am. Chem. Soc. 1972, 94, 4015-4017.
3. Meyer, B.; Weimar, T.; Peters, T. Screening mixtures for biological activity by NMR. Eur. J. Biochem. 1997, 246, 705-709.
4. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem., Int. Ed. 1999, 38, 1784-1788.
5. Chen, A.; Shapiro, M. A novel NMR technique for identification of compounds with binding affinity to macromolecules. J. Am. Chem. Soc. 1998, 120, 10258-10259.
6. Chen, A.; Shapiro, M. NOE pumping. 2. A high-throughput method to determine compounds with binding affinity to macromolecules by NMR. J. Am. Chem. Soc. 2000, 122, 414-415.
7. Dalvit, C.; Pevarello, P.; Tato, M.; Veronesi, M.; Vulpetti, A.; Sundstrom, M. Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR 2000, 18, 65-68.
8. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability. J. Biomol. NMR 2001, 21, 349-359.
9. Lin, M.; Shapiro, M. Mixture analysis in combinatorial chemistry. Application of diffusion-resolved NMR spectroscopy. J. Org. Chem. 1996, 61, 7617-7619.
10. Sanchez-Pedregal, V. M.; Reese, M.; Meiler, J.; Blommers, M. J. J.; Griesinger, C.; Carlomagno, T. The INPHARMA method: Protein-mediated interligand NOEs for pharmacophore mapping. Angew. Chem., Int. Ed. 2005, 44, 4172-4175.
11. Henrichsen, D.; Ernst, B.; Magnani, J.; Wang, W.; Meyer, B.; Peters, T. Bioaffinity NMR spectroscopy: Identification of an E-selectin antagonist in a substance mixture by transfer NOE. Angew. Chem., Int. Ed. 1999, 38, 98-102.
12. Jansson, A.; Wu, X.; Kavanagh, K.; Kerr, D.; Knox, R.; Walton, R.; Gunther, U.; Ludwig, C.; Edwards, A.; Arrowsmith, C.; Sundstrom, M.; von Delft, F.; Oppermann, U. PDB entry 1zx1.
13. Searle, P. F.; Chen, M. J.; Hu, L.; Race, P. R.; Lovering, A. L.; Grove, J. I.; Guise, C.; Jaberipour, M.; James, N. D.; Mautner, V.; Young, L. S.; Kerr, D. J.; Mountain, A.; White, S. A.; Hyde, E. I. Nitroreductase: A prodrug-activating enzyme for cancer gene therapy. Clin. Exp. Pharmacol. Physiol. 2004, 11, 811-816.
14. Dachs, G. U.; Tupper, J.; Tozer, G. M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005, 16, 349-359.